Norges Bank’s Amicus Therapeutics FOLD Stock Holding History

Norges Bank’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,165,028	Closed	-$16.6M	–	522
2025 Q4	$16.6M	Buy	+1,165,028	New	+$11.4M	﹤0.01%	1245
2025 Q3	–	Sell	-3,235,538	Closed	-$18.5M	–	586
2025 Q2	$18.5M	Hold	3,235,538	–	–	﹤0.01%	1198
2025 Q1	$26.4M	Buy	3,235,538 +153,502	+5%	+$1.42M	﹤0.01%	1146
2024 Q4	$29M	Buy	3,082,036 +157,391	+5%	+$1.64M	﹤0.01%	1155
2024 Q3	$31.2M	Hold	2,924,645	–	–	﹤0.01%	1132
2024 Q2	$29M	Sell	2,924,645 -1,434,681	-33%	-$14.7M	﹤0.01%	1114
2024 Q1	$51.4M	Buy	4,359,326 +1,828,326	+72%	+$23.4M	0.01%	934
2023 Q4	$35.9M	Buy	2,531,000 +114,683	+5%	+$1.3M	0.01%	1060
2023 Q3	$29.4M	Sell	2,416,317 -870,000	-26%	-$11.2M	0.01%	1071
2023 Q2	$41.3M	Sell	3,286,317 -1,883,102	-36%	-$22.3M	0.01%	949
2023 Q1	$57.3M	Sell	5,169,419 -230,667	-4%	-$2.84M	0.01%	773
2022 Q4	$65.9M	Buy	5,400,086 +1,043,346	+24%	+$11.7M	0.02%	688
2022 Q3	$45.5M	Buy	4,356,740 +1,511,838	+53%	+$16.8M	0.01%	811
2022 Q2	$30.6M	Buy	2,844,902 +379,744	+15%	+$3.13M	0.01%	1024
2022 Q1	$23.3M	Sell	2,465,158 -371,080	-13%	-$3.48M	0.01%	1318
2021 Q4	$32.8M	Buy	2,836,238 +73,557	+3%	+$820K	0.01%	1173
2021 Q3	$26.4M	Sell	2,762,681 -1,093,821	-28%	-$11.2M	0.01%	1310
2021 Q2	$37.2M	Buy	3,856,502 +1,667,810	+76%	+$16.3M	0.01%	1140
2021 Q1	$21.6M	Sell	2,188,692 -558,434	-20%	-$8.64M	0.01%	1502
2020 Q4	$63.4M	Sell	2,747,126 -963,604	-26%	-$19.7M	0.01%	815
2020 Q3	$52.4M	Sell	3,710,730 -437,019	-11%	-$6.37M	0.01%	821
2020 Q2	$62.5M	Buy	4,147,749 +550,279	+15%	+$6.71M	0.02%	704
2020 Q1	$33.2M	Buy	3,597,470 +169,133	+5%	+$1.61M	0.01%	920
2019 Q4	$33.4M	Buy	3,428,337 +925,238	+37%	+$8.47M	0.01%	1182
2019 Q3	$20.1M	Buy	2,503,099 +457,812	+22%	+$4.97M	0.01%	1475
2019 Q2	$25.5M	Buy	2,045,287 +483,402	+31%	+$6.13M	0.01%	1345
2019 Q1	$21.2M	Buy	1,561,885 +85,178	+6%	+$1.04M	0.01%	1463
2018 Q4	$14.1M	Hold	1,476,707	–	–	0.01%	1585
2018 Q3	$17.9M	Hold	1,476,707	–	–	0.01%	1593
2018 Q2	$23.1M	Hold	1,476,707	–	–	0.01%	1413
2018 Q1	$22.2M	Buy	1,476,707 +228,774	+18%	+$3.48M	0.01%	1363
2017 Q4	$18M	Hold	1,247,933	–	–	0.01%	1525
2017 Q3	$18.8M	Buy	1,247,933 +622,568	+100%	+$8.24M	0.01%	1486
2017 Q2	$6.3M	Sell	625,365 -147,492	-19%	-$1.19M	﹤0.01%	1850
2017 Q1	$5.51M	Sell	772,857 -246,005	-24%	-$1.56M	﹤0.01%	1868
2016 Q4	$5.06M	Hold	1,018,862	–	–	﹤0.01%	1860
2016 Q3	$7.2M	Buy	1,018,862 +167,832	+20%	+$1.13M	﹤0.01%	1782
2016 Q2	$4.65M	Buy	851,030 +171,000	+25%	+$1.2M	﹤0.01%	1885
2016 Q1	$5.75M	Hold	680,030	–	–	﹤0.01%	1789
2015 Q4	$6.6M	Sell	680,030 -98,717	-13%	-$890K	﹤0.01%	1794
2015 Q3	$10.9M	Buy	+778,747	New	+$12.2M	0.01%	1495

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Norges Bank's FOLD Position: Q1 2026 in Review

Norges Bank sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 1,165,028 shares — an estimated $16.6M sold.

Norges Bank first reported a position in FOLD in Q3 2015 and held it in 41 quarters. The position peaked at $65.9M in Q4 2022. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Norges Bank reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 1,165,028 Amicus Therapeutics shares in Q1 2026, an estimated $16.6M.
Norges Bank first reported a position in Amicus Therapeutics in Q3 2015 and held it in 41 quarters.
Norges Bank's Amicus Therapeutics position peaked at $65.9M in Q4 2022.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.